Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.

ABSTRACT: The mesenchymal-epithelial transition factor (c-MET) receptor is overexpressed in about 14-54% of invasive breast cancers, but its prognostic value in clinical practice is still unclear. In order to investigate the relationship between c-MET expression levels and prognosis, we retrospectively reviewed the clinical features and outcomes of 105 women with estrogen receptor positive HER2 negative (ER+/HER2-) resected breast cancer. We used the Kaplan Meier method to estimate Disease Free Survival (DFS) and Breast Cancer Specific Survival (BCSS) in the subgroups of patients with high (≥50%) and low (<50%) c-MET expression. Univariate and multivariate Cox proportional regression models were performed to assess the prognostic impact of clinicopathological parameters for DFS an BCSS. High c-ME

SUBMITTER: Iovino F 

PROVIDER: S-EPMC9738605 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature